|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Current assets: | |||||||||||||
| Cash | |||||||||||||
| Prepaid expenses | |||||||||||||
| Prepaid taxes | |||||||||||||
| Deferred business combination costs | |||||||||||||
| Total current assets | |||||||||||||
| Investment held in Trust Account | |||||||||||||
| Total assets | |||||||||||||
| Liabilities, redeemable shares and stockholders' deficit: | |||||||||||||
| Current liabilities: | |||||||||||||
| Accounts payable | |||||||||||||
| Accrued offering costs and expenses | |||||||||||||
| Accounts payable and accrued expenses | |||||||||||||
| Excises taxes payable | |||||||||||||
| Franchise tax payable | |||||||||||||
| Income taxes payable | |||||||||||||
| Due to related party | |||||||||||||
| Convertible promissory note at fair value - related party | |||||||||||||
| Total current liabilities | |||||||||||||
| Deferred tax liability | |||||||||||||
| Private warrant liability | |||||||||||||
| Total long-term liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Common stock subject to possible redemption, 2,359,298 and 2,878,178 shares outstanding at March 31, 2024 and December 31, 2023, respectively, at redemption value | |||||||||||||
| Common stock subject to possible redemption | |||||||||||||
| Total common stock subject to possible redemption, 2,359,298 and 2,878,178 shares outstanding at March 31, 2024 and December 31, 2023, respectively, at redemption value | |||||||||||||
| Stockholders' deficit: | |||||||||||||
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 5,640,000 shares issued and outstanding at both March 31, 2024 and December 31, 2023 (excluding shares subject to possible redemption of 2,359,298 and 2,878,178, respectively) | |||||||||||||
| Common stock not subject to possible redemption | |||||||||||||
| Total common stock, $0.0001 par value; 100,000,000 shares authorized; 5,640,000 shares issued and outstanding at both March 31, 2024 and December 31, 2023 (excluding shares subject to possible redemption of 2,359,298 and 2,878,178, respectively) | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders' deficit | |||||||||||||
| Total liabilities, redeemable shares and stockholders' deficit |
Loading...
